Characteristics of inverse probability of treatment-weighted cohorts at each landmark
| . | 12 months . | 15 months . | 18 months . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | ≥12 months (n = 1730) . | <12 months (n = 516) . | Standardized difference (%) . | ≥15 months (n = 1241) . | <15 months (n = 685) . | Standardized difference (%) . | ≥18 months (n = 963) . | <18 months (n = 728) . | Standardzed. difference (%) . |
| Age, years | 62.5 ± 10.2 | 62.6 ± 10.1 | −0.7 | 62.3 ± 10.0 | 62.3 ± 10.3 | 0.0 | 62.2 ± 10.0 | 62.2 ± 10.3 | 0.1 |
| Male, n (%) | 1113 (64.4) | 331 (64.2) | 0.5 | 805 (64.8) | 442 (64.5) | 0.7 | 625 (64.9) | 471 (64.7) | 0.3 |
| HD, n (%) | 1472 (85) | 439 (85) | 0.1 | 1060 (85) | 585 (85) | 0.3 | 822 (85) | 622 (85) | −0.3 |
| Information about index event | |||||||||
| ACS, n (%) | 1259 (72.8) | 375 (72.6) | 0.4 | 900 (72.6) | 498 (72.6) | −0.2 | 699 (72.6) | 529 (72.6) | −0.1 |
| Second-generation DES (versus first-generation), n (%) | 1437 (83.1) | 429 (83.2) | 0.2 | 1023 (82.5) | 565 (82.4) | −0.1 | 795 (82.5) | 602 (82.8) | 0.6 |
| Number of DES | 1 (1–6) | 1 (1–4) | −0.3 | 1 (1–6) | 1 (1–4) | −0.3 | 1 (1–6) | 1 (1–4) | 0.1 |
| Hospital days (days)a | 8 (1–30) | 8 (1–29) | −1.8 | 8 (1–30) | 8 (1–29) | 0.6 | 8 (1–30) | 8 (1–29) | 0.2 |
| Comorbidities, n (%) | |||||||||
| Hypertension | 1533 (88.6) | 454 (88.0) | 1.8 | 1107 (89.2) | 610 (89.0) | 0.5 | 644 (88.6) | 854 (88.6) | 0.2 |
| Atrial fibrillation | 50 (2.9) | 15 (2.9) | 0.1 | 36 (2.9) | 21 (3.0) | −0.7 | 20 (2.7) | 26 (2.7) | 0.0 |
| Valvular heart diseases | 18 (1.0) | 5 (1.0) | 0.4 | 14 (1.2) | 9 (1.3) | −1.0 | 7 (1.0) | 10 (1.1) | 0.5 |
| Lipid disorders | 1044 (60.4) | 314 (60.8) | −1.0 | 741 (59.7) | 411 (60.0) | −0.6 | 433 (59.5) | 571 (59.2) | −0.5 |
| CHF | 212 (12.3) | 64 (12.5) | −0.7 | 154 (12.4) | 85 (12.4) | −0.0 | 90 (12.4) | 120 (12.4) | 0.1 |
| PVD | 178 (10.3) | 52 (10.1) | 0.6 | 124 (10.0) | 68 (9.9) | 0.2 | 70 (9.7) | 94 (9.8) | 0.4 |
| CVA | 282 (16.3) | 85 (16.5) | −0.5 | 194 (15.6) | 108 (15.8) | −0.5 | 109 (15.0) | 145 (15.0) | 0.0 |
| Dementia | 45 (2.6) | 13 (2.6) | 0.1 | 33 (2.6) | 18 (2.7) | −0.4 | 17 (2.4) | 22 (2.3) | −0.6 |
| Pulmonary diseases | 440 (25.5) | 134 (25.9) | −1.0 | 313 (25.2) | 172 (25.1) | 0.3 | 174 (24.0) | 232 (24.0) | 0.2 |
| Connective tissue disorders | 39 (2.3) | 12 (2.3) | 0.0 | 29 (2.3) | 15 (2.2) | 0.4 | 17 (2.3) | 23 (2.4) | 0.4 |
| Peptic ulcer | 438 (25.3) | 132 (25.6) | −0.5 | 303 (24.4) | 166 (24.3) | 0.3 | 178 (24.4) | 237 (24.6) | 0.4 |
| Liver diseases | 47 (2.7) | 13 (2.6) | 0.9 | 34 (2.7) | 19 (2.8) | −0.4 | 18 (2.5) | 24 (2.5) | −0.1 |
| Diabetes | 926 (53.6) | 277 (53.6) | −0.1 | 655 (52.8) | 363 (52.9) | −0.3 | 373 (51.3) | 495 (51.4) | 0.3 |
| Cancer | 87 (5.0) | 28 (5.4) | −1.6 | 59 (4.8) | 33 (4.8) | −0.1 | 34 (4.7) | 47 (4.9) | 0.7 |
| Medication, n (%) | |||||||||
| α-blocker | 256 (14.8) | 77 (14.9) | −0.4 | 189 (15.2) | 101 (14.8) | 1.2 | 107 (14.8) | 145 (15.0) | 0.7 |
| Other antiplatelet agents | 275 (15.9) | 85 (16.4) | −1.4 | 195 (15.7) | 109 (15.8) | −0.3 | 115 (15.8) | 152 (15.8) | −0.1 |
| ACE inhibitor/ARB | 1229 (71.0) | 368 (71.3) | −0.5 | 884 (71.3) | 488 (71.2) | 0.1 | 519 (71.4) | 687 (71.3) | −0.2 |
| β-blocker | 695 (40.2) | 205 (39.7) | 1.0 | 508 (40.9) | 282 (41.1) | −0.5 | 300 (41.2) | 397 (41.3) | 0.1 |
| Calcium channel blocker | 1062 (61.4) | 315 (61.1) | 0.6 | 763 (61.5) | 421 (61.5) | 0.1 | 448 (61.6) | 592 (61.5) | −0.2 |
| Vasodilator | 156 (9.0) | 47 (9.1) | −0.2 | 113 (9.1) | 62 (9.1) | 0.1 | 64 (8.8) | 86 (8.9) | 0.4 |
| Loop diuretics | 822 (47.5) | 247 (47.8) | −0.6 | 594 (47.9) | 328 (47.9) | 0.1 | 345 (47.4) | 457 (47.4) | 0.0 |
| Statin | 788 (45.6) | 235 (45.6) | −0.0 | 562 (45.3) | 311 (45.4) | −0.1 | 329 (45.2) | 434 (45.1) | −0.3 |
| Other lipid-lowering agents | 88 (5.1) | 25 (4.8) | 1.2 | 59 (4.8) | 32 (4.7) | 0.3 | 35 (4.8) | 47 (4.8) | 0.2 |
| PPI | 427 (24.7) | 132 (25.6) | −2.2 | 299 (24.1) | 168 (24.5) | −1.1 | 173 (23.8) | 228 (23.7) | −0.3 |
| Other anti-ulcer medications | 857 (49.5) | 261 (50.5) | −2.0 | 597 (48.1) | 331 (48.3) | −0.3 | 346 (47.6) | 459 (47.7) | 0.2 |
| Nonselective NSAID | 845 (48.9) | 251 (48.6) | 0.5 | 599 (48.3) | 330 (48.1) | 0.2 | 350 (48.1) | 466 (48.3) | 0.5 |
| Cox2 inhibitor | 45 (2.6) | 13 (2.6) | 0.1 | 32 (2.6) | 17 (2.5) | 0.4 | 17 (2.4) | 24 (2.5) | 0.7 |
| . | 12 months . | 15 months . | 18 months . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | ≥12 months (n = 1730) . | <12 months (n = 516) . | Standardized difference (%) . | ≥15 months (n = 1241) . | <15 months (n = 685) . | Standardized difference (%) . | ≥18 months (n = 963) . | <18 months (n = 728) . | Standardzed. difference (%) . |
| Age, years | 62.5 ± 10.2 | 62.6 ± 10.1 | −0.7 | 62.3 ± 10.0 | 62.3 ± 10.3 | 0.0 | 62.2 ± 10.0 | 62.2 ± 10.3 | 0.1 |
| Male, n (%) | 1113 (64.4) | 331 (64.2) | 0.5 | 805 (64.8) | 442 (64.5) | 0.7 | 625 (64.9) | 471 (64.7) | 0.3 |
| HD, n (%) | 1472 (85) | 439 (85) | 0.1 | 1060 (85) | 585 (85) | 0.3 | 822 (85) | 622 (85) | −0.3 |
| Information about index event | |||||||||
| ACS, n (%) | 1259 (72.8) | 375 (72.6) | 0.4 | 900 (72.6) | 498 (72.6) | −0.2 | 699 (72.6) | 529 (72.6) | −0.1 |
| Second-generation DES (versus first-generation), n (%) | 1437 (83.1) | 429 (83.2) | 0.2 | 1023 (82.5) | 565 (82.4) | −0.1 | 795 (82.5) | 602 (82.8) | 0.6 |
| Number of DES | 1 (1–6) | 1 (1–4) | −0.3 | 1 (1–6) | 1 (1–4) | −0.3 | 1 (1–6) | 1 (1–4) | 0.1 |
| Hospital days (days)a | 8 (1–30) | 8 (1–29) | −1.8 | 8 (1–30) | 8 (1–29) | 0.6 | 8 (1–30) | 8 (1–29) | 0.2 |
| Comorbidities, n (%) | |||||||||
| Hypertension | 1533 (88.6) | 454 (88.0) | 1.8 | 1107 (89.2) | 610 (89.0) | 0.5 | 644 (88.6) | 854 (88.6) | 0.2 |
| Atrial fibrillation | 50 (2.9) | 15 (2.9) | 0.1 | 36 (2.9) | 21 (3.0) | −0.7 | 20 (2.7) | 26 (2.7) | 0.0 |
| Valvular heart diseases | 18 (1.0) | 5 (1.0) | 0.4 | 14 (1.2) | 9 (1.3) | −1.0 | 7 (1.0) | 10 (1.1) | 0.5 |
| Lipid disorders | 1044 (60.4) | 314 (60.8) | −1.0 | 741 (59.7) | 411 (60.0) | −0.6 | 433 (59.5) | 571 (59.2) | −0.5 |
| CHF | 212 (12.3) | 64 (12.5) | −0.7 | 154 (12.4) | 85 (12.4) | −0.0 | 90 (12.4) | 120 (12.4) | 0.1 |
| PVD | 178 (10.3) | 52 (10.1) | 0.6 | 124 (10.0) | 68 (9.9) | 0.2 | 70 (9.7) | 94 (9.8) | 0.4 |
| CVA | 282 (16.3) | 85 (16.5) | −0.5 | 194 (15.6) | 108 (15.8) | −0.5 | 109 (15.0) | 145 (15.0) | 0.0 |
| Dementia | 45 (2.6) | 13 (2.6) | 0.1 | 33 (2.6) | 18 (2.7) | −0.4 | 17 (2.4) | 22 (2.3) | −0.6 |
| Pulmonary diseases | 440 (25.5) | 134 (25.9) | −1.0 | 313 (25.2) | 172 (25.1) | 0.3 | 174 (24.0) | 232 (24.0) | 0.2 |
| Connective tissue disorders | 39 (2.3) | 12 (2.3) | 0.0 | 29 (2.3) | 15 (2.2) | 0.4 | 17 (2.3) | 23 (2.4) | 0.4 |
| Peptic ulcer | 438 (25.3) | 132 (25.6) | −0.5 | 303 (24.4) | 166 (24.3) | 0.3 | 178 (24.4) | 237 (24.6) | 0.4 |
| Liver diseases | 47 (2.7) | 13 (2.6) | 0.9 | 34 (2.7) | 19 (2.8) | −0.4 | 18 (2.5) | 24 (2.5) | −0.1 |
| Diabetes | 926 (53.6) | 277 (53.6) | −0.1 | 655 (52.8) | 363 (52.9) | −0.3 | 373 (51.3) | 495 (51.4) | 0.3 |
| Cancer | 87 (5.0) | 28 (5.4) | −1.6 | 59 (4.8) | 33 (4.8) | −0.1 | 34 (4.7) | 47 (4.9) | 0.7 |
| Medication, n (%) | |||||||||
| α-blocker | 256 (14.8) | 77 (14.9) | −0.4 | 189 (15.2) | 101 (14.8) | 1.2 | 107 (14.8) | 145 (15.0) | 0.7 |
| Other antiplatelet agents | 275 (15.9) | 85 (16.4) | −1.4 | 195 (15.7) | 109 (15.8) | −0.3 | 115 (15.8) | 152 (15.8) | −0.1 |
| ACE inhibitor/ARB | 1229 (71.0) | 368 (71.3) | −0.5 | 884 (71.3) | 488 (71.2) | 0.1 | 519 (71.4) | 687 (71.3) | −0.2 |
| β-blocker | 695 (40.2) | 205 (39.7) | 1.0 | 508 (40.9) | 282 (41.1) | −0.5 | 300 (41.2) | 397 (41.3) | 0.1 |
| Calcium channel blocker | 1062 (61.4) | 315 (61.1) | 0.6 | 763 (61.5) | 421 (61.5) | 0.1 | 448 (61.6) | 592 (61.5) | −0.2 |
| Vasodilator | 156 (9.0) | 47 (9.1) | −0.2 | 113 (9.1) | 62 (9.1) | 0.1 | 64 (8.8) | 86 (8.9) | 0.4 |
| Loop diuretics | 822 (47.5) | 247 (47.8) | −0.6 | 594 (47.9) | 328 (47.9) | 0.1 | 345 (47.4) | 457 (47.4) | 0.0 |
| Statin | 788 (45.6) | 235 (45.6) | −0.0 | 562 (45.3) | 311 (45.4) | −0.1 | 329 (45.2) | 434 (45.1) | −0.3 |
| Other lipid-lowering agents | 88 (5.1) | 25 (4.8) | 1.2 | 59 (4.8) | 32 (4.7) | 0.3 | 35 (4.8) | 47 (4.8) | 0.2 |
| PPI | 427 (24.7) | 132 (25.6) | −2.2 | 299 (24.1) | 168 (24.5) | −1.1 | 173 (23.8) | 228 (23.7) | −0.3 |
| Other anti-ulcer medications | 857 (49.5) | 261 (50.5) | −2.0 | 597 (48.1) | 331 (48.3) | −0.3 | 346 (47.6) | 459 (47.7) | 0.2 |
| Nonselective NSAID | 845 (48.9) | 251 (48.6) | 0.5 | 599 (48.3) | 330 (48.1) | 0.2 | 350 (48.1) | 466 (48.3) | 0.5 |
| Cox2 inhibitor | 45 (2.6) | 13 (2.6) | 0.1 | 32 (2.6) | 17 (2.5) | 0.4 | 17 (2.4) | 24 (2.5) | 0.7 |
Values for categorical variables are reported as count (percent), and for continuous variables, normally distributed ones are reported as the mean ± SD, and otherwise as the median with interquartile ranges. CHF, congestive heart failure; PVD, peripheral vascular diseases; CVA, cerebrovascular accident; ACE inhibitor/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; PPI, proton pump inhibitor; NSAID, nonsteroidal anti-inflammatory drug.
Length of hospital stay at admission for DES implantation.
Characteristics of inverse probability of treatment-weighted cohorts at each landmark
| . | 12 months . | 15 months . | 18 months . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | ≥12 months (n = 1730) . | <12 months (n = 516) . | Standardized difference (%) . | ≥15 months (n = 1241) . | <15 months (n = 685) . | Standardized difference (%) . | ≥18 months (n = 963) . | <18 months (n = 728) . | Standardzed. difference (%) . |
| Age, years | 62.5 ± 10.2 | 62.6 ± 10.1 | −0.7 | 62.3 ± 10.0 | 62.3 ± 10.3 | 0.0 | 62.2 ± 10.0 | 62.2 ± 10.3 | 0.1 |
| Male, n (%) | 1113 (64.4) | 331 (64.2) | 0.5 | 805 (64.8) | 442 (64.5) | 0.7 | 625 (64.9) | 471 (64.7) | 0.3 |
| HD, n (%) | 1472 (85) | 439 (85) | 0.1 | 1060 (85) | 585 (85) | 0.3 | 822 (85) | 622 (85) | −0.3 |
| Information about index event | |||||||||
| ACS, n (%) | 1259 (72.8) | 375 (72.6) | 0.4 | 900 (72.6) | 498 (72.6) | −0.2 | 699 (72.6) | 529 (72.6) | −0.1 |
| Second-generation DES (versus first-generation), n (%) | 1437 (83.1) | 429 (83.2) | 0.2 | 1023 (82.5) | 565 (82.4) | −0.1 | 795 (82.5) | 602 (82.8) | 0.6 |
| Number of DES | 1 (1–6) | 1 (1–4) | −0.3 | 1 (1–6) | 1 (1–4) | −0.3 | 1 (1–6) | 1 (1–4) | 0.1 |
| Hospital days (days)a | 8 (1–30) | 8 (1–29) | −1.8 | 8 (1–30) | 8 (1–29) | 0.6 | 8 (1–30) | 8 (1–29) | 0.2 |
| Comorbidities, n (%) | |||||||||
| Hypertension | 1533 (88.6) | 454 (88.0) | 1.8 | 1107 (89.2) | 610 (89.0) | 0.5 | 644 (88.6) | 854 (88.6) | 0.2 |
| Atrial fibrillation | 50 (2.9) | 15 (2.9) | 0.1 | 36 (2.9) | 21 (3.0) | −0.7 | 20 (2.7) | 26 (2.7) | 0.0 |
| Valvular heart diseases | 18 (1.0) | 5 (1.0) | 0.4 | 14 (1.2) | 9 (1.3) | −1.0 | 7 (1.0) | 10 (1.1) | 0.5 |
| Lipid disorders | 1044 (60.4) | 314 (60.8) | −1.0 | 741 (59.7) | 411 (60.0) | −0.6 | 433 (59.5) | 571 (59.2) | −0.5 |
| CHF | 212 (12.3) | 64 (12.5) | −0.7 | 154 (12.4) | 85 (12.4) | −0.0 | 90 (12.4) | 120 (12.4) | 0.1 |
| PVD | 178 (10.3) | 52 (10.1) | 0.6 | 124 (10.0) | 68 (9.9) | 0.2 | 70 (9.7) | 94 (9.8) | 0.4 |
| CVA | 282 (16.3) | 85 (16.5) | −0.5 | 194 (15.6) | 108 (15.8) | −0.5 | 109 (15.0) | 145 (15.0) | 0.0 |
| Dementia | 45 (2.6) | 13 (2.6) | 0.1 | 33 (2.6) | 18 (2.7) | −0.4 | 17 (2.4) | 22 (2.3) | −0.6 |
| Pulmonary diseases | 440 (25.5) | 134 (25.9) | −1.0 | 313 (25.2) | 172 (25.1) | 0.3 | 174 (24.0) | 232 (24.0) | 0.2 |
| Connective tissue disorders | 39 (2.3) | 12 (2.3) | 0.0 | 29 (2.3) | 15 (2.2) | 0.4 | 17 (2.3) | 23 (2.4) | 0.4 |
| Peptic ulcer | 438 (25.3) | 132 (25.6) | −0.5 | 303 (24.4) | 166 (24.3) | 0.3 | 178 (24.4) | 237 (24.6) | 0.4 |
| Liver diseases | 47 (2.7) | 13 (2.6) | 0.9 | 34 (2.7) | 19 (2.8) | −0.4 | 18 (2.5) | 24 (2.5) | −0.1 |
| Diabetes | 926 (53.6) | 277 (53.6) | −0.1 | 655 (52.8) | 363 (52.9) | −0.3 | 373 (51.3) | 495 (51.4) | 0.3 |
| Cancer | 87 (5.0) | 28 (5.4) | −1.6 | 59 (4.8) | 33 (4.8) | −0.1 | 34 (4.7) | 47 (4.9) | 0.7 |
| Medication, n (%) | |||||||||
| α-blocker | 256 (14.8) | 77 (14.9) | −0.4 | 189 (15.2) | 101 (14.8) | 1.2 | 107 (14.8) | 145 (15.0) | 0.7 |
| Other antiplatelet agents | 275 (15.9) | 85 (16.4) | −1.4 | 195 (15.7) | 109 (15.8) | −0.3 | 115 (15.8) | 152 (15.8) | −0.1 |
| ACE inhibitor/ARB | 1229 (71.0) | 368 (71.3) | −0.5 | 884 (71.3) | 488 (71.2) | 0.1 | 519 (71.4) | 687 (71.3) | −0.2 |
| β-blocker | 695 (40.2) | 205 (39.7) | 1.0 | 508 (40.9) | 282 (41.1) | −0.5 | 300 (41.2) | 397 (41.3) | 0.1 |
| Calcium channel blocker | 1062 (61.4) | 315 (61.1) | 0.6 | 763 (61.5) | 421 (61.5) | 0.1 | 448 (61.6) | 592 (61.5) | −0.2 |
| Vasodilator | 156 (9.0) | 47 (9.1) | −0.2 | 113 (9.1) | 62 (9.1) | 0.1 | 64 (8.8) | 86 (8.9) | 0.4 |
| Loop diuretics | 822 (47.5) | 247 (47.8) | −0.6 | 594 (47.9) | 328 (47.9) | 0.1 | 345 (47.4) | 457 (47.4) | 0.0 |
| Statin | 788 (45.6) | 235 (45.6) | −0.0 | 562 (45.3) | 311 (45.4) | −0.1 | 329 (45.2) | 434 (45.1) | −0.3 |
| Other lipid-lowering agents | 88 (5.1) | 25 (4.8) | 1.2 | 59 (4.8) | 32 (4.7) | 0.3 | 35 (4.8) | 47 (4.8) | 0.2 |
| PPI | 427 (24.7) | 132 (25.6) | −2.2 | 299 (24.1) | 168 (24.5) | −1.1 | 173 (23.8) | 228 (23.7) | −0.3 |
| Other anti-ulcer medications | 857 (49.5) | 261 (50.5) | −2.0 | 597 (48.1) | 331 (48.3) | −0.3 | 346 (47.6) | 459 (47.7) | 0.2 |
| Nonselective NSAID | 845 (48.9) | 251 (48.6) | 0.5 | 599 (48.3) | 330 (48.1) | 0.2 | 350 (48.1) | 466 (48.3) | 0.5 |
| Cox2 inhibitor | 45 (2.6) | 13 (2.6) | 0.1 | 32 (2.6) | 17 (2.5) | 0.4 | 17 (2.4) | 24 (2.5) | 0.7 |
| . | 12 months . | 15 months . | 18 months . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | ≥12 months (n = 1730) . | <12 months (n = 516) . | Standardized difference (%) . | ≥15 months (n = 1241) . | <15 months (n = 685) . | Standardized difference (%) . | ≥18 months (n = 963) . | <18 months (n = 728) . | Standardzed. difference (%) . |
| Age, years | 62.5 ± 10.2 | 62.6 ± 10.1 | −0.7 | 62.3 ± 10.0 | 62.3 ± 10.3 | 0.0 | 62.2 ± 10.0 | 62.2 ± 10.3 | 0.1 |
| Male, n (%) | 1113 (64.4) | 331 (64.2) | 0.5 | 805 (64.8) | 442 (64.5) | 0.7 | 625 (64.9) | 471 (64.7) | 0.3 |
| HD, n (%) | 1472 (85) | 439 (85) | 0.1 | 1060 (85) | 585 (85) | 0.3 | 822 (85) | 622 (85) | −0.3 |
| Information about index event | |||||||||
| ACS, n (%) | 1259 (72.8) | 375 (72.6) | 0.4 | 900 (72.6) | 498 (72.6) | −0.2 | 699 (72.6) | 529 (72.6) | −0.1 |
| Second-generation DES (versus first-generation), n (%) | 1437 (83.1) | 429 (83.2) | 0.2 | 1023 (82.5) | 565 (82.4) | −0.1 | 795 (82.5) | 602 (82.8) | 0.6 |
| Number of DES | 1 (1–6) | 1 (1–4) | −0.3 | 1 (1–6) | 1 (1–4) | −0.3 | 1 (1–6) | 1 (1–4) | 0.1 |
| Hospital days (days)a | 8 (1–30) | 8 (1–29) | −1.8 | 8 (1–30) | 8 (1–29) | 0.6 | 8 (1–30) | 8 (1–29) | 0.2 |
| Comorbidities, n (%) | |||||||||
| Hypertension | 1533 (88.6) | 454 (88.0) | 1.8 | 1107 (89.2) | 610 (89.0) | 0.5 | 644 (88.6) | 854 (88.6) | 0.2 |
| Atrial fibrillation | 50 (2.9) | 15 (2.9) | 0.1 | 36 (2.9) | 21 (3.0) | −0.7 | 20 (2.7) | 26 (2.7) | 0.0 |
| Valvular heart diseases | 18 (1.0) | 5 (1.0) | 0.4 | 14 (1.2) | 9 (1.3) | −1.0 | 7 (1.0) | 10 (1.1) | 0.5 |
| Lipid disorders | 1044 (60.4) | 314 (60.8) | −1.0 | 741 (59.7) | 411 (60.0) | −0.6 | 433 (59.5) | 571 (59.2) | −0.5 |
| CHF | 212 (12.3) | 64 (12.5) | −0.7 | 154 (12.4) | 85 (12.4) | −0.0 | 90 (12.4) | 120 (12.4) | 0.1 |
| PVD | 178 (10.3) | 52 (10.1) | 0.6 | 124 (10.0) | 68 (9.9) | 0.2 | 70 (9.7) | 94 (9.8) | 0.4 |
| CVA | 282 (16.3) | 85 (16.5) | −0.5 | 194 (15.6) | 108 (15.8) | −0.5 | 109 (15.0) | 145 (15.0) | 0.0 |
| Dementia | 45 (2.6) | 13 (2.6) | 0.1 | 33 (2.6) | 18 (2.7) | −0.4 | 17 (2.4) | 22 (2.3) | −0.6 |
| Pulmonary diseases | 440 (25.5) | 134 (25.9) | −1.0 | 313 (25.2) | 172 (25.1) | 0.3 | 174 (24.0) | 232 (24.0) | 0.2 |
| Connective tissue disorders | 39 (2.3) | 12 (2.3) | 0.0 | 29 (2.3) | 15 (2.2) | 0.4 | 17 (2.3) | 23 (2.4) | 0.4 |
| Peptic ulcer | 438 (25.3) | 132 (25.6) | −0.5 | 303 (24.4) | 166 (24.3) | 0.3 | 178 (24.4) | 237 (24.6) | 0.4 |
| Liver diseases | 47 (2.7) | 13 (2.6) | 0.9 | 34 (2.7) | 19 (2.8) | −0.4 | 18 (2.5) | 24 (2.5) | −0.1 |
| Diabetes | 926 (53.6) | 277 (53.6) | −0.1 | 655 (52.8) | 363 (52.9) | −0.3 | 373 (51.3) | 495 (51.4) | 0.3 |
| Cancer | 87 (5.0) | 28 (5.4) | −1.6 | 59 (4.8) | 33 (4.8) | −0.1 | 34 (4.7) | 47 (4.9) | 0.7 |
| Medication, n (%) | |||||||||
| α-blocker | 256 (14.8) | 77 (14.9) | −0.4 | 189 (15.2) | 101 (14.8) | 1.2 | 107 (14.8) | 145 (15.0) | 0.7 |
| Other antiplatelet agents | 275 (15.9) | 85 (16.4) | −1.4 | 195 (15.7) | 109 (15.8) | −0.3 | 115 (15.8) | 152 (15.8) | −0.1 |
| ACE inhibitor/ARB | 1229 (71.0) | 368 (71.3) | −0.5 | 884 (71.3) | 488 (71.2) | 0.1 | 519 (71.4) | 687 (71.3) | −0.2 |
| β-blocker | 695 (40.2) | 205 (39.7) | 1.0 | 508 (40.9) | 282 (41.1) | −0.5 | 300 (41.2) | 397 (41.3) | 0.1 |
| Calcium channel blocker | 1062 (61.4) | 315 (61.1) | 0.6 | 763 (61.5) | 421 (61.5) | 0.1 | 448 (61.6) | 592 (61.5) | −0.2 |
| Vasodilator | 156 (9.0) | 47 (9.1) | −0.2 | 113 (9.1) | 62 (9.1) | 0.1 | 64 (8.8) | 86 (8.9) | 0.4 |
| Loop diuretics | 822 (47.5) | 247 (47.8) | −0.6 | 594 (47.9) | 328 (47.9) | 0.1 | 345 (47.4) | 457 (47.4) | 0.0 |
| Statin | 788 (45.6) | 235 (45.6) | −0.0 | 562 (45.3) | 311 (45.4) | −0.1 | 329 (45.2) | 434 (45.1) | −0.3 |
| Other lipid-lowering agents | 88 (5.1) | 25 (4.8) | 1.2 | 59 (4.8) | 32 (4.7) | 0.3 | 35 (4.8) | 47 (4.8) | 0.2 |
| PPI | 427 (24.7) | 132 (25.6) | −2.2 | 299 (24.1) | 168 (24.5) | −1.1 | 173 (23.8) | 228 (23.7) | −0.3 |
| Other anti-ulcer medications | 857 (49.5) | 261 (50.5) | −2.0 | 597 (48.1) | 331 (48.3) | −0.3 | 346 (47.6) | 459 (47.7) | 0.2 |
| Nonselective NSAID | 845 (48.9) | 251 (48.6) | 0.5 | 599 (48.3) | 330 (48.1) | 0.2 | 350 (48.1) | 466 (48.3) | 0.5 |
| Cox2 inhibitor | 45 (2.6) | 13 (2.6) | 0.1 | 32 (2.6) | 17 (2.5) | 0.4 | 17 (2.4) | 24 (2.5) | 0.7 |
Values for categorical variables are reported as count (percent), and for continuous variables, normally distributed ones are reported as the mean ± SD, and otherwise as the median with interquartile ranges. CHF, congestive heart failure; PVD, peripheral vascular diseases; CVA, cerebrovascular accident; ACE inhibitor/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; PPI, proton pump inhibitor; NSAID, nonsteroidal anti-inflammatory drug.
Length of hospital stay at admission for DES implantation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
